<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26707">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01864915</url>
  </required_header>
  <id_info>
    <org_study_id>DMED 1578-13</org_study_id>
    <secondary_id>9427-D2773-21C</secondary_id>
    <nct_id>NCT01864915</nct_id>
  </id_info>
  <brief_title>Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule</brief_title>
  <official_title>Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gastrointestinal Diseases Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colon capsule endoscopy is a new technology that is a noninvasive method of examining the
      large bowel. The bowel preparation required for this test differs from colonoscopy in that
      it needs to clean the colon but also needs to provide propulsion. Most published studies
      have used medications as part of their regime that are not available in parts of North
      America (ex. sodium phosphate) and have shown poor test completion, bowel preparation and
      polyp detection rates.

      Objective: In this study a bowel preparation for the colon capsule is proposed that uses
      medications approved for use in Canada that may provide a better preparation quality and
      better completion rates.

      Methods: Patients who are being referred for a colonoscopy will be recruited to participate
      in the study. They will all receive split-dose polyethylene glycol (PEG) for bowel
      preparation. They will be randomized to receive either 1) Prucalopride 2mg daily for four
      days, 2) Prucalopride 2mg daily for four days plus a Prucalopride booster, or 3)
      Prucalopride 2mg for four days plus 1 and 1/2 sachets of Picosalax boosters for the colon
      capsule study.  The day after the colon capsule they will drink PEG 2L at 5am ( or approx
      4hrs prior to procedure time and return for a colonoscopy.  The colon capsule results will
      be reviewed by two endoscopists experienced in video capsule endoscopy who will assess the
      bowel preparation using a previously defined scale and examine for polyps. We propose that
      administering Prucalopride daily for 4 days will increase intestinal motility and improve
      colon capsule completion rates and a booster dose of Picosalax will improve colon capsule
      completion rates compared to prucalopride by itself.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>To assess the quality of the bowel preparations</measure>
    <time_frame>Day of colon capsule procedure and day of colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Colon capsule bowel prep assessed with previously used scale completed by designated gastroenterologists.
Colonoscopy bowel prep assessed by completion of Aronchick Scale by endoscopist performing procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance of Bowel Preparation with survey</measure>
    <time_frame>Day of colonoscopy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric, small bowel and colon transit time</measure>
    <time_frame>Day of colon capsule</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bowel Preparation</condition>
  <condition>Colon Capsule Completion Rates</condition>
  <arm_group>
    <arm_group_label>No Booster-low dose prucalopride booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose prucalopride booster arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prucalopride Booster-high dose prucalopride booster</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>additional 2mg prucalopride at time of capsule ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Picosalax Booster Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <description>Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)</description>
    <arm_group_label>No Booster-low dose prucalopride booster</arm_group_label>
    <arm_group_label>Prucalopride Booster-high dose prucalopride booster</arm_group_label>
    <arm_group_label>Picosalax Booster Arm</arm_group_label>
    <other_name>RESTORAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colon Capsule</intervention_name>
    <description>Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.</description>
    <arm_group_label>No Booster-low dose prucalopride booster</arm_group_label>
    <arm_group_label>Prucalopride Booster-high dose prucalopride booster</arm_group_label>
    <arm_group_label>Picosalax Booster Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the ages of 18-75 being referred for colonoscopy

        Exclusion Criteria:

          -  symptoms of dysphagia or any problems with swallowing, bowel obstruction or ileus,
             known stricture or fistula, inflammatory bowel disease, previous small or large bowel
             surgery, severe gastroparesis or motility disorder, severe renal impairment ( defined
             as eGFR less than 55 within three months of study), congestive heart failure (NYHA
             III or IV), ischemic heart disease (acute event in the last 6mths), decompensated
             cirrhosis or severe hepatic dysfunction (ascites or known INR&gt;2), history of serious
             arrhythmia or any other severe and clinically unstable concomitant disease (eg. lung
             disease, neurological or psychiatric disorder, cancer, AIDS and other endocrine
             disorder) ,diabetics on treatment with insulin or hypoglycemic, pregnant or nursing
             women, galactose intolerance (since the tablets contain lactose monohydrate, patients
             with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency
             or glucose/galactose malabsorption must not take this medicinal product.) or known
             hypersensitivity to the drug or to any ingredient in the formulation (each  2mg
             tablet contains prucalopride 2 mg. Nonmedicinal ingredients: tablet core: lactose
             monohydrate, microcrystalline cellulose, colloidal silicon dioxide, and magnesium
             stearate; coating: hypromellose, lactose monohydrate, triacetin, titanium dioxide,
             macrogol 3000, iron oxide red, iron oxide yellow, and FD&amp;C Blue No. 2 Aluminum Lake)
             Females of child bearing potential who are unwilling to use appropriate birth control
             methods during the study will not be able to participate in this clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Hookey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lawrence Hookey, MD</last_name>
    <phone>613-544-3400</phone>
    <phone_ext>2292</phone_ext>
    <email>hookeyl@hdh.kari.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darlene Brady</last_name>
    <phone>613-544-3400</phone>
    <phone_ext>2445</phone_ext>
    <email>bradyd@hdh.kari.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hotel Dieu Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Hookey</last_name>
      <phone>613-544-3400</phone>
      <phone_ext>2292</phone_ext>
      <email>hookeyl@hdh.kari.net</email>
    </contact>
    <investigator>
      <last_name>Stephen Vanner</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Marchut</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Kelley</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Paterson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>May 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Lawrence Hookey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>colon capsule</keyword>
  <keyword>bowel preparation</keyword>
  <keyword>booster</keyword>
  <keyword>prucalopride</keyword>
  <keyword>picosalax</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
